Lumida
/ACTG
⌘K
Acacia Research Corp

Acacia Research Corp

ACTG
$4.57USD↑+0.00%+0.00 today

MARKET CAP

446.0M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$3
$5

AI Summary

Stalk
TrimMedium

ACTG remains in a Stage 4 decline with a medium-term bearish bias reinforced by the Bearish Pivot Point pattern and lower highs under the 50-day SMA. Short-term conditions are neutral, as price holds just below flattening 9/20/50 EMAs without clear momentum. We will look to sell into rebounds toward those EMAs and the 50-day SMA, aiming for rejection-based entries. The long-term uptrend above the 200-day SMA persists, providing structural support but not overriding current downtrend pressures.

  • ↑Q2 revenue $114.6M (+124% YoY) driven by acquisitions
  • ↑$334.6M cash on hand, no parent debt enables opportunistic M&A
  • ↓Licensing rev variability; $3.7M legal costs strain cash flow
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Acacia Research Corporation (NASDAQ:ACTG) operates as a diversified investment firm focusing on acquiring businesses across sectors and improving their operations. The company emphasizes building long-term value through prudent capital allocation and leveraging its intellectual property platform. Acacia is involved in sectors including energy, manufacturing, and technology licensing, with a notable commitment to strategic acquisitions, particularly in niche markets.

Bull says

  • ↑Q2 revenue $114.6M (+124% YoY) driven by acquisitions
  • ↑$334.6M cash on hand, no parent debt enables opportunistic M&A
  • ↑Management cites strongest-ever deal flow for strategic buys
  • ↑~1% dividend yield and strong momentum reflect investor confidence
  • ↑Book-to-price ratio of 1.46 suggests undervaluation
  • ↑Wi-Fi 6 licensing and oil-sensitive assets offer growth upside

Bear says

  • ↓Licensing rev variability; $3.7M legal costs strain cash flow
  • ↓Deflecto’s slow ramp highlights manufacturing operational bottlenecks
  • ↓High rates and small size may inflate acquisition costs
  • ↓Regulatory hurdles in life sciences deals pose setback risks
  • ↓Negative profitability and liquidity factors signal operational stress
  • ↓Episodic IP deals create revenue unpredictability

Earnings Call · Q1 2024 · Mgmt. Guidance

Updated 05-13-2025bullish

Transcript signals

Bull points

  • a press release disclosing the financial results was issued this afternoon just after the close of market.
  • $439 million
  • $460 million

Bear points

  • We had some receivables as of the end of December from our IP group that were all collected in the quarter. That was really the biggest driver of the increase. Sorry -- and also, as we mentioned, in the fourth quarter, we recorded an unrealized gain on our Arix investment for the forward sale contract that we had. That closed also in the quarter and turned to cash.
  • We're evaluating it on a consistent basis, and we are seeing a lot of opportunities to deploy cash into acquisitions. So we -- when we think it is opportunistic, we'll buy stock back. And if we don't think, it's opportunistic or it's less opportunistic than making acquisitions, then we use cash to make acquisitions.
  • As a reminder, the AIP Matter relates to an ongoing legal matter, involving a Profits Interest Plan adopted by prior members of management and the Board in 2017.
Read full transcript analysis ›